Dean P Kwak

Array ( [id] => 16774207 [patent_doc_number] => 10985331 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Organic electroluminescent materials and devices [patent_app_type] => utility [patent_app_number] => 16/927297 [patent_app_country] => US [patent_app_date] => 2020-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9525 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 235 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16927297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770822 [patent_doc_number] => 10981910 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Biaryl kinase inhibitors [patent_app_type] => utility [patent_app_number] => 16/913064 [patent_app_country] => US [patent_app_date] => 2020-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 52511 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16913064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16649941 [patent_doc_number] => 10927103 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-02-23 [patent_title] => Organic electroluminescent compound and organic electroluminescent device comprising the same [patent_app_type] => utility [patent_app_number] => 16/897422 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7865 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16897422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16800157 [patent_doc_number] => 10995078 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-04 [patent_title] => Compounds and compositions for inhibition of FASN [patent_app_type] => utility [patent_app_number] => 15/929751 [patent_app_country] => US [patent_app_date] => 2020-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48370 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 2461 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15929751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16549717 [patent_doc_number] => 10882866 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-01-05 [patent_title] => Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors [patent_app_type] => utility [patent_app_number] => 16/844473 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38421 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 488 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16844473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590512 [patent_doc_number] => 10899762 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Organic compounds [patent_app_type] => utility [patent_app_number] => 16/786240 [patent_app_country] => US [patent_app_date] => 2020-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11976 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16786240 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268771 [patent_doc_number] => 20200270258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => NOVEL SELECTIVE PI3K DELTA INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/776327 [patent_app_country] => US [patent_app_date] => 2020-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16776327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15848103 [patent_doc_number] => 10639312 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-05-05 [patent_title] => Finished pharmaceutical dosage form of a methenamine salt such as methenamine mandelate [patent_app_type] => utility [patent_app_number] => 16/705414 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2817 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16705414 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527079 [patent_doc_number] => 20200055845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => KRAS G12C INHIBITORS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/661907 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77164 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16661907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16649940 [patent_doc_number] => 10927102 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Crystalline forms of posaconazole intermediate and process for the preparation of amorphous posaconazole [patent_app_type] => utility [patent_app_number] => 16/655632 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5074 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222695 [patent_doc_number] => 20200247811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/593588 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10876 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15768673 [patent_doc_number] => 20200115354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/576569 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16369010 [patent_doc_number] => 10800750 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Compounds and compositions for inhibition of FASN [patent_app_type] => utility [patent_app_number] => 16/566119 [patent_app_country] => US [patent_app_date] => 2019-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48342 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16566119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460735 [patent_doc_number] => 10844069 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Pyrrolotriazine compounds as TAM inhibitors [patent_app_type] => utility [patent_app_number] => 16/559841 [patent_app_country] => US [patent_app_date] => 2019-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69247 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16559841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236703 [patent_doc_number] => 20200253937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME [patent_app_type] => utility [patent_app_number] => 16/541337 [patent_app_country] => US [patent_app_date] => 2019-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31726 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16541337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16125837 [patent_doc_number] => 10696658 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Heteroaromatic compounds and their use as dopamine D1 ligands [patent_app_type] => utility [patent_app_number] => 16/539865 [patent_app_country] => US [patent_app_date] => 2019-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45557 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1304 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16539865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163165 [patent_doc_number] => 10487062 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-11-26 [patent_title] => Regioselective one-step process for synthesizing 2-hydroxyquinoxaline [patent_app_type] => utility [patent_app_number] => 16/529371 [patent_app_country] => US [patent_app_date] => 2019-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2772 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16529371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15342505 [patent_doc_number] => 20200009144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => Combination Therapy Comprising Varlitinib and an Anticancer Agent [patent_app_type] => utility [patent_app_number] => 16/508444 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7766 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16444842 [patent_doc_number] => 10836754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol [patent_app_type] => utility [patent_app_number] => 16/503245 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5180 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16503245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15407841 [patent_doc_number] => 20200024242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => LOW-ENERGY CONSUMPTION PROCESS WITH REDUCED AMMONIA CONSUMPTION, FOR THE PRODUCTION OF HIGH-PURITY MELAMINE THROUGH THE PYROLYSIS OF UREA, AND RELATIVE PLANT [patent_app_type] => utility [patent_app_number] => 16/458343 [patent_app_country] => US [patent_app_date] => 2019-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9751 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 346 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16458343 [rel_patent_id] =>[rel_patent_doc_number] =>)